Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Crunch Time For 15 New Drugs At Final CHMP Meeting Of 2021

Oral Explanation Meetings Possible For Four Marketing Applications

Executive Summary

Drugs for COVID-19, Alzheimer’s disease and heavy menstrual bleeding due to uterine fibroids are among the latest products that are this week being considered for marketing approval by the European Medicine Agency’s human drugs evaluation committee, the CHMP.

You may also be interested in...



Novel Sickle Cell Treatment Among 13 New Drugs On Track For EU Approval

A first-of-its-kind drug for uterine fibroids and a new monoclonal antibody treatment for COVID-19 are among several new drugs recommended for pan-EU approval this month.

Intercept Withdraws EU NASH Drug Filing But May Retry

New data that is being collected to support a US resubmission for Intercept’s obeticholic acid might also be used to support a resubmission to the European Medicines Agency.

COVID-19 Treatment Xevudy Wins UK Approval; Preclinical Data Shows Promise Against Omicron

New developments on the COVID-19 front also include the European Medicines Agency starting a rolling review of Valneva’s investigational COVID-19 vaccine, and the UK government signing contracts with Pfizer/BioNTech and Moderna to buy more doses of their vaccines.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS145388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel